HAGENS BERMAN, NATIONAL SECURITIES LAW FIRM, Encourages CVRx, Inc. (CVRX) Investors with Substantial Losses to Contact Firm, Securities Class Action Filed

Résumé détaillé

SAN FRANCISCO, Nov. 13, 2026 /PRNewswire/ -- Hagens Berman, a national shareholder rights litigation firm, alerts investors in CVRx, Inc. (NASDAQ: CVRX) to a class action lawsuit…

SAN FRANCISCO, Nov. 13, 2026 /PRNewswire/ -- Hagens Berman, a national shareholder rights litigation firm, alerts investors in CVRx, Inc. (NASDAQ: CVRX) to a class action lawsuit filed in federal court. The filing follows disclosures of a U.S. Department of Justice Civil Investigative Demand ("CID"), severe cuts to revenue guidance, commercial sales force disruption, and the sudden termination of the company's Chief Revenue Officer.

CVRx ,Inc. (NASDAQ: CVRX) Investors: Investors who suffered substantial losses are encouraged to submit your losses now to evaluate their legal rights and recovery options.

Class Period: July 25, 2023 – Aug. 6, 2026Lead Plaintiff Deadline: Jan. 8, 2026Visit: www.hbsslaw.com/cvrx Direct Contact Email: [email protected] Firm Telephone: 844-916-0895Blog: www.hbsslaw.com/blog/implantable-devices-and-the-defibrillation-of-reality-cvrx-inc-cvrx

CVRx's sole commercial product is Barostim, an FDA-approved implantable neuromodulation device designed to improve symptoms for patients suffering from heart failure. Historically, CVRx assured investors that its growth strategy was anchored by a complete sales force transformation and high approval rates from Medicare Advantage payers.

CVRx repeatedly highlighted a "$10.5 billion market opportunity" with less than 1% penetration, reassuring the market earlier this year that its sales force transformation was "largely complete."

However, after market close on August 6, 2026, CVRx disclosed a series of severe operational and legal headwinds:

In response to these revelations, CVRx's stock price cratered 60% on August 7, 2026.

Three days later, on August 10, 2026, CVRx abruptly terminated its Chief Revenue Officer (CRO), Robert John.

"We are investigating whether CVRx may have misled investors regarding the true state of its commercial sales force and Medicare Advantage reimbursement rates, as the complaint alleges," said Reed Kathrein, a Hagens Berman partner.

Début de l'article, extrait de PR Newswire. Pour lire la suite, ouvrez l'article chez le média.